Zhen-Yu Zhang1,2, Vannina G Marrachelli3,4, Wen-Yi Yang1,2, Sander Trenson5, Qi-Fang Huang1, Fang-Fei Wei1, Lutgarde Thijs1, Jan Van Keer5, Daniel Monleon3, Peter Verhamme6, Jens-Uwe Voigt5, Tatiana Kuznetsova1, Josep Redón3,7,8,9, Jan A Staessen1,10. 1. 1 Research Unit Hypertension and Cardiovascular Epidemiology, University of Leuven, Belgium. 2. 2 Department of Cardiology, Shanghai General Hospital, China. 3. 3 Metabolomic and Molecular Image Laboratory, Fundación Investigatión Clínico de Valencia (INCLIVA), Spain. 4. 4 Department of Physiology, University of Valencia, Valencia, Spain. 5. 5 Research Unit Cardiology, University of Leuven, Belgium. 6. 6 Centre for Molecular and Vascular Biology, University of Leuven, Belgium. 7. 7 Hypertension Unit, University of Valencia, Spain. 8. 8 Centro de Investigación Biomédica de la Fisiopatología de la Obesidad y la Nutrición (CIBERObn), Ministerio de Ciencia e Innovación, Spain. 9. 9 Instituto de Salud Carlos III, Spain. 10. 10 Cardiovascular Research Institute (CARIM), Maastricht University, The Netherlands.
Abstract
AIMS: We studied the association of circulating metabolic biomarkers with asymptomatic left ventricular diastolic dysfunction, a risk-carrying condition that affects 25% of the population. METHODS AND RESULTS: In 570 randomly recruited people, we assessed in 2005-2010 and in 2009-2013 the multivariable-adjusted correlations of e' (early left ventricular relaxation) and E/e' (left ventricular filling pressure) measured by Doppler echocardiography with 43 serum metabolites, quantified by magnetic resonance spectroscopy. In 2009-2013, e' cross-sectionally increased (Bonferroni corrected p ≤ 0.016) with the branched-chain amino acid valine (per one standard deviation increment, +0.274 cm/s (95% confidence interval, 0.057-0.491)) and glucose+the amino acid (AA) taurine (+0.258 cm/s (0.067-0.481)), while E/e' decreased ( p ≤ 0.017) with valine (-0.264 (-0.496- -0.031)). The risk of developing left ventricular diastolic dysfunction over follow-up (9.4%) was inversely associated ( p ≤ 0.0059) with baseline glucose+amino acid taurine (odds ratio, 0.64 (0.44-0.94). In partial least squares analyses of all the baseline and follow-up data, markers consistently associated with better diastolic left ventricular function included the amino acids 2-aminobutyrate and 4-hydroxybutyrate and the branched-chain amino acids leucine and valine, and those consistently associated with worse diastolic left ventricular function glucose+amino acid glutamine and fatty acid pentanoate. Branched-chain amino acid metabolism (-log10 p = 12.6) and aminoacyl-tRNA biosynthesis (9.9) were among the top metabolic pathways associated with left ventricular diastolic dysfunction. CONCLUSION: The associations of left ventricular diastolic dysfunction with circulating amino acids and branched-chain amino acids were consistent over a five-year interval and suggested a key role of branched-chain amino acid metabolism and aminoacyl-tRNA biosynthesis in maintaining diastolic left ventricular function.
AIMS: We studied the association of circulating metabolic biomarkers with asymptomatic left ventricular diastolic dysfunction, a risk-carrying condition that affects 25% of the population. METHODS AND RESULTS: In 570 randomly recruited people, we assessed in 2005-2010 and in 2009-2013 the multivariable-adjusted correlations of e' (early left ventricular relaxation) and E/e' (left ventricular filling pressure) measured by Doppler echocardiography with 43 serum metabolites, quantified by magnetic resonance spectroscopy. In 2009-2013, e' cross-sectionally increased (Bonferroni corrected p ≤ 0.016) with the branched-chain amino acidvaline (per one standard deviation increment, +0.274 cm/s (95% confidence interval, 0.057-0.491)) and glucose+the amino acid (AA) taurine (+0.258 cm/s (0.067-0.481)), while E/e' decreased ( p ≤ 0.017) with valine (-0.264 (-0.496- -0.031)). The risk of developing left ventricular diastolic dysfunction over follow-up (9.4%) was inversely associated ( p ≤ 0.0059) with baseline glucose+amino acid taurine (odds ratio, 0.64 (0.44-0.94). In partial least squares analyses of all the baseline and follow-up data, markers consistently associated with better diastolic left ventricular function included the amino acids 2-aminobutyrate and 4-hydroxybutyrate and the branched-chain amino acids leucine and valine, and those consistently associated with worse diastolic left ventricular function glucose+amino acid glutamine and fatty acid pentanoate. Branched-chain amino acid metabolism (-log10 p = 12.6) and aminoacyl-tRNA biosynthesis (9.9) were among the top metabolic pathways associated with left ventricular diastolic dysfunction. CONCLUSION: The associations of left ventricular diastolic dysfunction with circulating amino acids and branched-chain amino acids were consistent over a five-year interval and suggested a key role of branched-chain amino acid metabolism and aminoacyl-tRNA biosynthesis in maintaining diastolic left ventricular function.
Entities:
Keywords:
Biomarker; branched-chain amino acids; diastolic left ventricular dysfunction; metabolomics; population science
Authors: Eileen Ruth S Torres; Reed Hall; Gerd Bobe; Jaewoo Choi; Soren Impey; Carl Pelz; Jonathan R Lindner; Jan F Stevens; Jacob Raber Journal: Front Mol Biosci Date: 2019-09-10
Authors: Alexander C Razavi; Lydia A Bazzano; Jiang He; Camilo Fernandez; Seamus P Whelton; Marie Krousel-Wood; Shengxu Li; Jovia L Nierenberg; Mengyao Shi; Changwei Li; Xuenan Mi; Jason Kinchen; Tanika N Kelly Journal: J Am Heart Assoc Date: 2020-01-29 Impact factor: 5.501
Authors: Sharon Remmelzwaal; Joline W J Beulens; Petra J M Elders; Coen D A Stehouwer; Zhenyu Zhang; M Louis Handoko; Yolande Appelman; Vanessa van Empel; Stephane R B Heymans; Lutgarde Thijs; Jan A Staessen; A Johanne van Ballegooijen Journal: PLoS One Date: 2021-05-04 Impact factor: 3.240
Authors: Dries S Martens; Lutgarde Thijs; Agnieszka Latosinska; Sander Trenson; Justyna Siwy; Zhen-Yu Zhang; Congrong Wang; Joachim Beige; Antonia Vlahou; Stefan Janssens; Harald Mischak; Tim S Nawrot; Jan A Staessen Journal: Lancet Healthy Longev Date: 2021-11